Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Trop Med Hyg ; 97(2): 567-574, 2017 08.
Artigo em Inglês | MEDLINE | ID: mdl-28722637

RESUMO

Schistosomiasis remains one of the most prevalent parasitic diseases worldwide and the infection is frequently found in travelers and migrants. The European Network for Tropical Medicine and Travel Health conducted a sentinel surveillance study on imported schistosomiasis between 1997 and 2010. This report summarizes epidemiological and clinical data from 1,465 cases of imported schistosomiasis. Direct pathogen detection and serology were the main diagnostic tools applied. Of these, 486 (33%) cases were identified among European travelers, 231 (16%) among long-term expatriates, and 748 (51%) among non-European immigrants. Overall, only 18.6% of travelers had received pretravel advice; 95% of infections were acquired in the African region. On species level, Schistosoma mansoni was identified in 570 (39%) and Schistosoma haematobium in 318 (22%) cases; 57.5% of patients were symptomatic. Acute symptoms were reported in 27% of patients leading to earlier presentation within 3 months. Praziquantel was used in all patients to treat schistosomiasis. Many infections were detected in asymptomatic patients. In 47.4% of asymptomatic patients infection was detected by microscopy and in 39% by serology or antigen testing. Schistosomiasis remains a frequent infection in travelers and migrants to Europe. Travelers should be made aware of the risk of schistosomiasis infection when traveling to sub-Saharan Africa. Posttravel consultations particularly for returning expatriates are useful given the high potential for detecting asymptomatic infections.


Assuntos
Anti-Helmínticos/uso terapêutico , Praziquantel/uso terapêutico , Esquistossomose/diagnóstico , Adolescente , Adulto , África Subsaariana/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Animais , Criança , Pré-Escolar , Europa (Continente)/epidemiologia , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Prevalência , Esquistossomose/tratamento farmacológico , Esquistossomose/epidemiologia , Migrantes/estatística & dados numéricos , Viagem/estatística & dados numéricos , Adulto Jovem
2.
J Travel Med ; 20(2): 83-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23464714

RESUMO

BACKGROUND: Outbreaks of histoplasmosis have been increasingly reported in association with travel to endemic areas. Multiple outbreaks have been reported following travel to the Americas, but reports of pulmonary histoplasmosis in short-term immunocompetent travelers to Africa are rare. METHODS: A biology student was referred to our unit with suspected pulmonary histoplasmosis following her return from a field trip in the Ugandan rainforest. The patient informed us that several of her multinational student colleagues on the same expedition had developed a similar illness. Using an alert in ProMED-mail and a questionnaire forwarded to each of the symptomatic students, we accumulated data on the other cases involved in this apparent outbreak of pulmonary histoplasmosis. RESULTS: Thirteen of 24 students developed respiratory symptoms following the expedition. Chest X-ray appearances were often suggestive of miliary tuberculosis but in most cases a final diagnosis of histoplasmosis was made (confirmed with serology in five cases, clinically diagnosed in six, and retrospectively suspected in two). Detailed questioning indicated that the likely source was a large hollow bat-infested tree within the rainforest. CONCLUSIONS: This is an unusual outbreak of histoplasmosis following short-term travel to Africa. Pulmonary histoplasmosis should always be considered in the differential diagnosis of an acute febrile respiratory illness in travelers returning from endemic areas or reporting activities suggesting exposure.


Assuntos
Surtos de Doenças , Histoplasma/imunologia , Histoplasmose , Pneumopatias Fúngicas , Combinação Amoxicilina e Clavulanato de Potássio/administração & dosagem , Animais , Antibacterianos/administração & dosagem , Anticorpos Antifúngicos/sangue , Quirópteros , Claritromicina/administração & dosagem , Diagnóstico Diferencial , Vetores de Doenças , Feminino , Histoplasmose/diagnóstico , Histoplasmose/fisiopatologia , Histoplasmose/terapia , Histoplasmose/transmissão , Humanos , Pulmão/diagnóstico por imagem , Pneumopatias Fúngicas/diagnóstico , Pneumopatias Fúngicas/etiologia , Pneumopatias Fúngicas/fisiopatologia , Pneumopatias Fúngicas/terapia , Pneumopatias Fúngicas/transmissão , Masculino , Radiografia , Viagem , Uganda/epidemiologia , Adulto Jovem
3.
J Infect Dis ; 190(9): 1541-6, 2004 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-15478057

RESUMO

BACKGROUND: Two single-point mutations of the Plasmodium falciparum cytochrome b gene (Tyr268Asn and Tyr268Ser) were recently reported in cases of atovaquone/proguanil (Malarone) treatment failure. However, little is known about the prevalence of codon-268 mutations and their quantitative association with treatment failure. METHODS: We set out to assess the prevalence of codon-268 mutations in P. falciparum isolates imported into Europe and to quantify their association with atovaquone/proguanil treatment failure. Isolates of P. falciparum collected by the European Network on Imported Infectious Disease Surveillance between April 2000 and August 2003 were analyzed for codon-268 mutations, by use of polymerase chain reaction-restriction fragment-length polymorphism. RESULTS: We successfully screened 504 samples for the presence of either Tyr268Ser or Tyr268Asn. One case of Ser268 and no cases of Asn268 were detected. Therefore, we can be 95% confident that the prevalence of Ser268 in the European patient pool does not exceed 0.96% and that Asn268 is less frequent than 0.77%. In 58 patients treated with atovaquone/proguanil, Tyr268Ser was present in 1 of 5 patients with treatment failure but in 0 of 53 successfully treated patients. CONCLUSIONS: Tyr268Ser seems to be a sufficient, but not a necessary, cause for atovaquone/proguanil treatment failure. The prevalence of both codon-268 mutations is currently unlikely to be >1% in the European patient pool.


Assuntos
Antimaláricos/farmacologia , Malária Falciparum/parasitologia , Naftoquinonas/farmacologia , Plasmodium falciparum/efeitos dos fármacos , Plasmodium falciparum/genética , Mutação Puntual , Proguanil/farmacologia , Adolescente , Adulto , Idoso , Substituição de Aminoácidos , Animais , Atovaquona , Códon , Citocromos b/genética , Citocromos b/fisiologia , DNA de Protozoário/análise , DNA de Protozoário/isolamento & purificação , Combinação de Medicamentos , Resistência a Medicamentos/genética , Europa (Continente) , Feminino , Genes de Protozoários , Humanos , Malária Falciparum/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Epidemiologia Molecular , Mutação de Sentido Incorreto , Naftoquinonas/uso terapêutico , Plasmodium falciparum/isolamento & purificação , Polimorfismo de Fragmento de Restrição , Proguanil/uso terapêutico , Proteínas de Protozoários/genética , Proteínas de Protozoários/fisiologia , Falha de Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...